- Home
- ARQQ vs MNPR Comparison
ARQQ vs MNPR Comparison
Compare ARQQ & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- MNPR
- Stock Information
- Founded
- ARQQ 2017
- MNPR 2014
- Country
- ARQQ United Kingdom
- MNPR United States
- Employees
- ARQQ N/A
- MNPR N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ARQQ Technology
- MNPR Health Care
- Exchange
- ARQQ Nasdaq
- MNPR Nasdaq
- Market Cap
- ARQQ 282.1M
- MNPR 250.0M
- IPO Year
- ARQQ N/A
- MNPR 2019
- Fundamental
- Price
- ARQQ $16.00
- MNPR $40.25
- Analyst Decision
- ARQQ Strong Buy
- MNPR Strong Buy
- Analyst Count
- ARQQ 1
- MNPR 4
- Target Price
- ARQQ $52.00
- MNPR $43.00
- AVG Volume (30 Days)
- ARQQ 458.5K
- MNPR 70.2K
- Earning Date
- ARQQ 12-05-2024
- MNPR 03-27-2025
- Dividend Yield
- ARQQ N/A
- MNPR N/A
- EPS Growth
- ARQQ N/A
- MNPR N/A
- EPS
- ARQQ N/A
- MNPR N/A
- Revenue
- ARQQ $293,000.00
- MNPR N/A
- Revenue This Year
- ARQQ $1,818.77
- MNPR N/A
- Revenue Next Year
- ARQQ N/A
- MNPR N/A
- P/E Ratio
- ARQQ N/A
- MNPR N/A
- Revenue Growth
- ARQQ N/A
- MNPR N/A
- 52 Week Low
- ARQQ $3.72
- MNPR $1.72
- 52 Week High
- ARQQ $52.79
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ARQQ 36.51
- MNPR 49.34
- Support Level
- ARQQ $15.32
- MNPR $38.80
- Resistance Level
- ARQQ $17.00
- MNPR $45.60
- Average True Range (ATR)
- ARQQ 1.43
- MNPR 5.19
- MACD
- ARQQ -0.20
- MNPR -1.50
- Stochastic Oscillator
- ARQQ 11.41
- MNPR 9.37
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.